PharmAthene Terminates Merger With Theraclone Sciences

Dec. 02, 2013 11:13 AM ETALT
adspatz profile picture
adspatz's Blog
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Contributor Since 2013

Aaron Spatz is the writer of SEC Live Filings Digest, detailing the news of companies trading on U.S. stock exchanges. The Filings Digest is but one component of the greater website SEC Live, which specializes in making SEC filings easy to read, research, navigate, and much more.

Originally published at

PharmAthene, Inc. (PIP) has terminated its merger agreement with Theraclone Sciences, Inc., after reaching an agreement with Theraclone. Had the merger been executed, a wholly-owned subsidiary of PharmAthene would have merged with Theraclone in an all-stock deal. Because PharmAthene has now cancelled the merger and its special meeting with shareholders, it will pay Theraclone a termination fee in the amount of $1M. PharmAthene is a bio-defense company that specializes in medical countermeasures to biological and chemical threats. Its flagship products include countermeasures for anthrax and nerve agents. PharmAthene President and CEO Eric Richman expressed his gratitude for the hard work put forth by both companies during the last several months to close the transaction and affirmed its enthusiasm to identify opportunities to provide shareholders maximum value.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.